Related by context. All words. (Click for frequent words.) 70 pharmacokinetics PK 70 pharmacodynamic PD 70 pharmacokinetic PK 70 favorable pharmacokinetic profile 69 CIMZIA ™ 69 teriflunomide 69 pharmacodynamic effects 69 pharmacokinetic characteristics 68 oral prodrug 68 APTIVUS 68 Xanafide 68 viral kinetics 68 pharmacokinetic parameters 68 pharmacokinetic PK study 68 GAMMAGARD 68 Pharmacokinetic parameters 68 inecalcitol 67 glycosylated hemoglobin HbA1c 67 maximally tolerated dose 67 HuMax EGFr 67 pharmacodynamic profile 67 serum cortisol 67 dose proportionality 67 #mg dose [001] 67 INCB# [001] 67 MP4OX 67 Pharmacokinetic PK 67 pharmacokinetic profile 67 Pharmacodynamic 67 pharmacodynamic properties 67 pharmacokinetic pharmacodynamic 67 serum concentrations 67 alicaforsen enema 67 pramlintide metreleptin combination 67 vidofludimus 67 BAL# [002] 67 pharmacodynamic parameters 67 CIMZIA TM 66 ritonavir boosted 66 biodistribution 66 dosage regimens 66 YONDELIS 66 coadministration 66 administered subcutaneously 66 immune modulatory 66 glycemia 66 Dasatinib 66 antiviral efficacy 66 Adalimumab 66 PRTX 66 liposomal formulation 66 serum phosphorous 66 fosbretabulin 66 Virulizin ® 66 orally dosed 66 decitabine 66 relapsed MM 66 CTAP# Capsules 66 NN# [001] 66 certolizumab 66 metabolic parameters 66 Tasimelteon 66 sargramostim 66 receptor inhibitor 66 serum LDL cholesterol 66 LAB CGRP 66 AST ALT 66 GPx 66 Lp PLA 2 66 BENICAR HCT 66 preclinical pharmacokinetic 66 tolerability profiles 66 Pharmacokinetic 66 serum phosphorus levels 66 pain palliation 66 pharmacodynamics PD 66 CANCIDAS 66 DCCR 65 hematological parameters 65 PSN# [002] 65 cinacalcet 65 lomitapide 65 ISIS # 65 PS# [001] 65 Phase Ib study 65 aplindore 65 canakinumab 65 lipid parameters 65 GLP1 agonist 65 TPMT 65 Insulin PH# 65 preclinical efficacy 65 GHRH 65 DAVANAT 65 plasma pharmacokinetics 65 analgesic efficacy 65 selective modulator 65 prucalopride 65 Pharmacokinetics PK 65 HoFH 65 AGHD 65 urocortin 2 65 epoetin alpha 65 ULORIC 65 Azedra 65 solithromycin 65 rHuPH# 65 GFT# 65 inhaled iloprost 65 Interferon alpha 65 antitumor efficacy 65 PROMACTA 65 clevidipine 65 galiximab 65 crizotinib PF # 65 Iloperidone 65 serum lipid levels 65 Sym# 65 somatostatin analogues 65 glycated hemoglobin levels 65 glatiramer acetate 65 CCX# 65 thorough QT 65 intravenous dosing 65 lispro 65 ascending dose 65 Carbaglu ® 65 pharmacokinetic profiles 65 oral rivaroxaban 65 serum phosphate 65 cannabinor 65 Zemplar Capsules 65 Saforis 65 Cystatin C 65 μg kg 65 riociguat 65 HCV replicon 65 intermittent dosing 65 topoisomerase II inhibitor 64 Kahalalide F 64 #mg dose [002] 64 GLYX 64 Omacetaxine mepesuccinate 64 Dual Opioid 64 calcitonin 64 pitavastatin 64 dosage regimen 64 AZILECT R 64 iPTH 64 Privigen 64 CaPre TM 64 Forodesine HCl 64 antibody titer 64 GLP toxicology studies 64 serum phosphorus 64 beta 1a 64 bronchodilation 64 preclinically 64 IFN α 64 trodusquemine 64 R#/MEM # 64 triiodothyronine 64 Decitabine 64 Phase 1a clinical 64 CLORETAZINE TM VNP#M 64 ARB telmisartan 64 NPH insulin 64 platelet inhibitor 64 MYCAMINE 64 Akt activation 64 Traficet EN 64 Trandolapril 64 MAGE A3 ASCI 64 ruxolitinib 64 serum TSH 64 mg/m2 cohort 64 cMET 64 serum urate 64 subcutaneously administered 64 Telmisartan 64 ADAGIO study 64 sUA 64 vivo potency 64 calculated creatinine clearance 64 pharmacodynamic 64 Androxal TM 64 guanfacine extended release 64 interferon alfa 2b 64 blood Phe 64 6mg 64 platelet inhibition 64 oral FTY# 64 Darusentan 64 FOSRENOL ® 64 Plicera 64 corrected QT interval 64 isoenzyme 64 Nilotinib 64 QTc prolongation 64 novel VDA molecule 64 tacrolimus ointment 64 glomerular filtration 64 6R BH4 64 Elvitegravir 64 desvenlafaxine succinate 64 Primary endpoints 64 HER2 expression 64 Tezampanel 64 XmAb# 64 clinically meaningful improvement 64 BEXXAR Therapeutic Regimen 64 biologic DMARD 64 TREDAPTIVE 64 Symadex 64 eprotirome 64 C1 INH 64 HbA1C 64 TNFalpha 64 vitro cytotoxicity 64 Ceplene/IL-2 64 cobiprostone 64 baseline HbA1c 64 pharmacodynamic markers 64 hemoglobin A1c HbA1c 64 pharmacokinetic interactions 64 dosing cohort 64 INVEGA ® 64 icatibant 64 ORMD 64 Tekamlo 64 budesonide foam 64 Vidaza azacitidine 64 uricase 63 Pioglitazone 63 teduglutide 63 dose cohort 63 apolipoprotein B 63 azilsartan medoxomil 63 tolerability pharmacokinetics 63 salmeterol fluticasone 63 Epanova 63 paricalcitol 63 microdose 63 PEG IFN 63 AZILECT ® 63 INCB# [003] 63 Fondaparinux 63 Natalizumab 63 nucleotide analog 63 Pharmacokinetic studies 63 undetectable HBV DNA 63 PRT# 63 Phase Ia 63 CoFactor 63 serum lipid 63 posaconazole 63 Golimumab 63 K ras mutations 63 interferon IFN 63 ZOLINZA 63 Inhalation Solution 63 PSMA ADC 63 Oral NKTR 63 virological response 63 plasma lipid 63 Randomized Double blind 63 ancrod 63 adrenocorticotropic hormone 63 Acute Ischemic Stroke 63 Cardiotoxicity 63 Interferon beta 1a 63 Zoraxel 63 neratinib 63 tissue oxygenation 63 dosing frequency 63 pharmacokinetics pharmacodynamics 63 leukotriene B4 63 selegiline 63 effector function 63 lanreotide 63 CINQUIL 63 ACTEMRA TM 63 atherogenic lipids 63 macrolide antibiotic 63 mertansine 63 blood Phe levels 63 Non inferiority 63 intact parathyroid hormone 63 nicardipine 63 DPP4 63 indibulin 63 PROCHYMAL 63 IgG antibody 63 colesevelam HCl 63 Menadione 63 Degarelix 63 glulisine 63 hyperphenylalaninemia HPA due 63 albumin excretion rate 63 USL# 63 immune modulating 63 rFIXFc 63 EVIZON 63 antiangiogenic agents 63 generation purine nucleoside 63 serum uric acid 63 BENICAR 63 FSH CTP 63 busulfan 63 secondary efficacy endpoints 63 pharmacokinetic properties 63 IFN gamma 63 LHRH antagonists 63 Anticalins ® 63 Protelos 63 tasimelteon 63 Plenaxis TM 63 Moxifloxacin 63 SGPT 63 evaluating tivozanib 63 Elitek 63 antiviral potency 63 pharmacokinetic studies 63 Teriflunomide 63 CTA# 63 fluvastatin 63 APRISO 63 non nucleoside 63 tolerability 63 azelaic acid 63 oral bioavailability 63 Liraglutide 63 Betaferon R 63 double blinded placebo 63 peak plasma concentrations 63 AEGR 63 brivaracetam 63 HIV RNA 63 Phase IIIb clinical 63 EDARBI 63 Phase 1a 63 STRIDE PD 63 UPLYSO 63 NOX E# 63 MoxDuo TM IR 63 natriuretic peptide 63 MIRCERA 63 ATL# [001] 63 Pemetrexed 63 IFN beta 63 ENMD # 63 Capesaris 63 parathyroid hormone PTH 63 velafermin 63 prasterone 63 pyridostigmine 63 insulin detemir 63 Cimzia TM 63 visilizumab 63 Ranolazine 63 Arikace 63 isoproterenol 63 FOLPI 63 MERLIN TIMI 63 timepoints 63 Rasilez Tekturna 63 Ophena TM 63 tanespimycin 63 PHX# 63 ataluren 63 caspofungin 63 LY# [003] 62 plasma renin activity 62 efficacy endpoint 62 Antiviral Activity 62 AeroLEF TM 62 ascending doses 62 ToGA 62 zileuton 62 UGT#A# 62 specific IgE 62 serum urate levels 62 TNF Tumor Necrosis Factor 62 Creatinine 62 insulin sensitizing 62 CYT# QbG# 62 AGILECT R 62 EGFR HER2 62 safety tolerability pharmacokinetic 62 fasting plasma glucose FPG 62 zonisamide SR 62 liver histology 62 fasting plasma 62 QVA# 62 XIENCE V PROMUS Stent 62 elotuzumab 62 Valdoxan 62 multicentre randomized 62 corticosteroid dexamethasone 62 HuMax CD# 62 lactate dehydrogenase LDH 62 plasma concentrations 62 fasting plasma glucose 62 dose escalation phase 62 Posiphen 62 hepatic enzymes 62 HQK 62 Twinrix 62 radiation dosimetry 62 APTIVUS r 62 convenient dosing regimens 62 F FDG PET 62 serum calcium 62 postprandial glycemia 62 CRLX# 62 PEGylated interferon 62 liposomal doxorubicin 62 MEND CABG 62 glycosylated hemoglobin levels 62 haematologic 62 erythropoietic 62 R# #mg BID 62 ganetespib 62 Thorough QT 62 pomalidomide 62 sipuleucel T 62 DLTs 62 CG# [003] 62 fulvestrant 62 Pimavanserin 62 Diovan HCT 62 trastuzumab emtansine T DM1 62 azacytidine 62 teriparatide 62 Focalin XR 62 antiangiogenic therapy 62 rilonacept 62 systemic bioavailability 62 GW# [003] 62 vWF 62 GSK# [001] 62 pharmacodynamic endpoints 62 Keppra XR 62 Tiotropium 62 aspartate aminotransferase AST 62 Vildagliptin 62 Humate P 62 alanine aminotransferase ALT 62 Elagolix 62 phase IIb study 62 Aptivus ® 62 pharmacokinetics 62 thymalfasin 62 octreotide implant 62 vildagliptin 62 huN# DM1 62 INT# [002] 62 wilate ® 62 forodesine 62 ACAPODENE 62 PRE SURGE 62 demonstrated clinically meaningful 62 Mipomersen 62 EQUETRO 62 MoxDuo IR 62 dosing interval 62 pharmacokinetic 62 tarenflurbil 62 abacavir lamivudine 62 parasitemia 62 Telintra 62 Cleviprex TM clevidipine 62 TriRima 62 orally inhaled 62 YERVOY 62 serum PTH 62 FAMPYRA 62 CRMD# 62 ACE Inhibitor 62 steroid dexamethasone 62 leukotriene receptor antagonist 62 irbesartan 62 enzastaurin 62 oral renin inhibitor 62 bezafibrate 62 Carfilzomib 62 nalbuphine ER 62 d dimer 62 pegylated IFN 62 Laquinimod 62 anti HBs 62 QD dosing 62 colorectal liver metastases 62 dose proportional pharmacokinetics 62 IIa trials 62 MYDICAR 62 ALISTA 62 VKORC1 62 Teriparatide 62 cardiac repolarization 62 tesofensine 62 ara C 62 deferasirox 62 mg kg BID 62 lanthanum carbonate 62 mcg dose 62 RhuDex ® 62 thyrotropin 62 plasma glucose 62 Phase 2a trial 62 serum leptin 62 randomized Phase 2b 62 HBeAg seroconversion 62 JAK Inhibitor 62 naltrexone SR 62 NNT = 62 triglyceride concentrations 62 Candesartan 62 Cardiorespiratory fitness 62 immunostaining 62 PET tracers 62 Belerofon 62 LY# [002] 62 sitosterol 62 LB# [003] 62 C Reactive Protein 62 synthetic retinoid 62 total cholesterol triglycerides 62 Sitagliptin 62 Interferon Beta 62 omega interferon 62 postdose 62 anticancer activity 62 CIMZIA TM certolizumab pegol 62 Omacetaxine 62 eosinophil count 62 ACCORD Lipid 62 Solorel TM 62 metabolite concentrations 62 HIF 1a 62 AZOR 62 nonclinical studies 62 SERCA2a 62 QT QTc 62 florbetaben 62 concentration Cmax 62 Tolerability 62 fluticasone salmeterol 62 dopamine partial agonist 62 TPI ASM8 62 postprandial blood glucose 62 Pertuzumab 62 mGlu2 3 62 oral methylnaltrexone 62 topically administered 62 OGTT 62 PI3K Akt 62 RhuDex 62 eculizumab therapy 62 RE LY ® 62 pioglitazone HCl 62 PDE4 inhibitor 62 antitumor effect 62 See CLINICAL PHARMACOLOGY 62 RLY# 62 plasma lipoprotein 62 metastatic neuroendocrine tumors 62 Dose Response 62 antiarrhythmic drug 62 CDK inhibitor 62 ThGRF 62 SCIg 62 selective agonist 62 eliglustat tartrate 62 DACH platinum 62 adalimumab 62 Tasigna prolongs 62 complete cytogenetic response 62 Estrogen Receptor 62 achieved statistical significance 62 iloprost 62 ALVESCO HFA 62 eNO 62 tipifarnib 62 Degludec 62 L PPDS 62 genotypic resistance 62 ACE inhibitor ramipril 62 MEVACOR 62 immunomodulation 62 Triolex 62 antidepressant efficacy 62 Lubiprostone 62 efalizumab 62 Low Density Lipoprotein Cholesterol 62 dasatinib Sprycel 61 candesartan cilexetil 61 Beta catenin pathway 61 prospectively defined 61 Gastrointestinal Stromal Tumors 61 Tipranavir 61 IRX 2 61 Durezol 61 reactogenicity 61 amifostine 61 PCWP 61 Alkaline Phosphatase 61 Telbivudine 61 ritonavir boosting 61 liposomal amphotericin B 61 BRIM3 61 apolipoproteins 61 factor Xa 61 B7 H3 61 Dabigatran etexilate 61 cardioprotective effects 61 TLK# 61 TH# [003] 61 hsCRP levels 61 octreotide LAR 61 cytoreductive nephrectomy 61 p# biomarker 61 secondary efficacy endpoint 61 Vidofludimus 61 active moiety 61 mesalazine 61 Factor IX 61 tipranavir r 61 serotonin norepinephrine reuptake inhibitor 61 erlotinib Tarceva ® 61 acitretin 61 mecamylamine 61 leukocyte count 61 NovoLog ® Mix 61 EOquin TM 61 dose dependently 61 insulin degludec 61 Archexin 61 detemir 61 renal toxicity 61 tubulin inhibitor 61 GOUT 61 Noxafil 61 triglyceride lowering 61 selective adenosine 61 Peginterferon 61 alemtuzumab MS 61 trospium 61 lumbar spine BMD 61 ATACAND 61 CA9 SCAN 61 hepatic fibrosis 61 #beta estradiol 61 Phase Ib II 61 EGS# 61 Betaferon ® 61 TIMP 1 61 Actilon 61 PASI scores 61 Melphalan 61 SVR# 61 Secondary endpoints 61 Tolvaptan 61 TMC# r 61 chlorambucil 61 LCP Tacro TM 61 DermaVir Patch 61 biostatistical analysis 61 myeloperoxidase 61 ChronVac C R 61 CYT# potent vascular disrupting 61 TRIOLEX 61 Amphinex ® 61 Bezielle 61 clinical pharmacology studies 61 HOMA IR 61 lymphocyte counts 61 Cyclosporine 61 ISTODAX 61 orally bioavailable 61 randomized blinded 61 abacavir Ziagen 61 Bronchial Thermoplasty 61 enoximone 61 dose titration 61 Anacetrapib 61 Pharmacodynamics 61 Tarceva TM 61 hA# 61 vivo validation 61 Wellmune WGP 61 SPRIX ® 61 bioequivalency 61 Fulvestrant 61 Bevirimat 61 Anticalin ® 61 efficacy tolerability 61 NATRECOR R 61 serum retinol 61 PON1 enzyme 61 Cinacalcet HCl 61 ESBA# 61 latanoprost 61 vismodegib 61 Varespladib 61 Hizentra 61 trough FEV1 61 lipoprotein Lp 61 melphalan prednisone 61 Kepivance 61 active comparator 61 insulin lispro 61 SAR# [002] 61 CardioPET 61 Poly ICLC 61 LibiGel ® 61 glucose homeostasis 61 peginterferon alfa 2a #KD 61 Egrifta 61 transgene expression 61 Omiganan 61 MGd 61 pegylated interferons 61 adenoma recurrence 61 nab paclitaxel 61 Orally administered 61 hemoglobin Hb 61 zoledronate 61 antioxidant supplementation 61 Universal Flu Vaccine 61 Zyclara 61 nanomolar range 61 peak VO2 61 HBsAg 61 exendin 4 61 adenosine injection 61 varespladib 61 SPIRIT FIRST 61 RAS mutations 61 bovine thrombin 61 sitaxsentan 61 Th1 type 61 Targretin capsules 61 olmesartan 61 intranasal formulation 61 randomized multicenter trial 61 Benazepril 61 Alocrest 61 oral diclofenac 61 ARIKACE 61 muscarinic 61 LT NS# 61 Vernakalant 61 Phase #b/#a trial 61 docetaxel Taxotere ® 61 antiresorptive 61 safety tolerability pharmacokinetics 61 LCP Tacro ™ 61 successfully commercialize Iluvien 61 5 Fluorouracil 61 evaluable subjects 61 novel histone deacetylase 61 Mg Usa 61 Solorel 61 radezolid 61 Thrombin 61 VAPRISOL 61 Clinical Relevance 61 daunorubicin 61 histone deacetylase inhibitor 61 Ocrelizumab 61 endoscopic remission 61 Indacaterol 61 airway hyper responsiveness 61 PEG PAL 61 Multimeric 61 VEGF inhibitor 61 mucosal healing 61 SIMCOR 61 NNRTI resistant virus 61 hour bronchodilation 61 Valortim R 61 ZD# [001] 61 dnaJP1 61 pramlintide 61 Silodosin 61 cardiac perfusion 61 hERG 61 hMG 61 Tyrosine Kinase Inhibitor 61 Chemophase 61 tolvaptan 61 plasma kallikrein 61 triglyceride TG 61 ularitide 61 Eligen R B# 61 Zoledronic acid 61 rBChE 61 PDE#A 61 inhaled AAT 61 lipid profiles 61 MGN# 61 immunological responses 61 Quinamed 61 alefacept 61 hsCRP 61 Hyphanox 61 dose limiting toxicities 61 brachial artery flow 61 CHAMPION PCI 61 culture supernatants 61 inflammatory biomarkers 61 plasma uric acid 61 Parathyroid Hormone 61 thymidylate synthase TS 61 growth hormone secretion 61 dexpramipexole 61 pan HDAC inhibitor 61 ORENCIA R 61 Dacogen decitabine 61 GAMMAGARD LIQUID 61 Vitaxin 61 HbA 1C 61 tigecycline 61 myopathy rhabdomyolysis 61 incretin 61 TNF α 61 CONCERTA 61 plasma kallikrein inhibitor 61 #.#mg/dL 61 partial agonist 61 oral antidiabetic medication 61 XOMA 3AB 61 tolerability profile 61 intradermal injection 61 isatoribine 61 Aliskiren 61 miglustat 61 antiapoptotic 61 homocysteine concentrations 61 multicenter randomized placebo controlled 61 polymerase inhibitor 61 CAPHOSOL 61 GnRH antagonist 61 topical diclofenac 61 DAPT 61 Double Blind Randomized 61 KB# [002] 61 pharmacodynamics 61 Prostate AdenoCarcinoma Treatment 61 Onconase 61 treprostinil 61 Pegylated Liposomal Doxorubicin 61 posttreatment 61 selenium supplementation 61 carotid IMT 61 ImmuKnow 61 Phase Ib clinical 61 relapsed MCL 61 fluticasone furoate 61 #μg [001] 61 ALA PDT 61 immunosuppressive regimen 61 PITX2 methylation 61 mg/m2 dose 61 serum testosterone 61 protease inhibitor PI 61 BEXXAR 61 Safinamide 61 pharmacodynamic profiles 61 Calcium Acetate 61 TURBT 61 TMC# [002] 61 KRAS mutation 61 pertuzumab 61 tecarfarin 61 Granulocyte Colony Stimulating Factor 61 idraparinux 61 Enzastaurin 61 bile acid sequestrant 61 RE LY trial 61 Dapagliflozin 61 aminotransferases 61 radiolabeled 61 tumorigenicity 61 standard chemotherapy regimen 61 postprandial glucose 61 Bosutinib 61 Aortic Stenosis 61 Hsp# Inhibitor 61 trastuzumab Herceptin 61 #F FDG PET 61 oblimersen 61 delafloxacin 61 Myocardial Perfusion Imaging 61 JAK inhibitor 61 low dose cytarabine 61 Immunogenicity 61 #D#C# 61 Lenalidomide 61 Engerix B 61 serum IgG 61 Darinaparsin 61 nucleotide analogue 61 N telopeptide 61 fumagillin nanoparticles 61 serum HCV RNA 61 Bicifadine 61 FASLODEX 61 Pivotal Phase III 61 mTOR inhibition 61 adrenal function 61 Inosine 61 PENNVAX B 61 alvimopan 61 PRISTIQ 61 demonstrated antitumor activity 61 CaPre ™ 61 exploratory endpoints 60 CYT# 60 Velcade bortezomib 60 Randomized Phase 60 PEGylated anti 60 serum aminotransferase levels 60 epigenetic therapies 60 ATL/TV# 60 serum homocysteine 60 Genz # 60 Bortezomib 60 transaminases 60 EBMT criteria 60 bortezomib Velcade 60 DAS# CRP 60 regorafenib 60 metastatic malignant 60 Ophena 60 IL #E 60 acromegalic patients 60 sodium glucose cotransporter 60 small molecule activators 60 Neulasta ® 60 balsalazide 60 levodopa carbidopa 60 elacytarabine 60 Prospective Randomized 60 TOLAMBA 60 transdermal estradiol 60 Lisofylline 60 INC# 60 Anticalins R 60 ug kg 60 Posaconazole 60 Glufosfamide 60 Denufosol 60 gastric pH 60 intratumoral 60 LDL Cholesterol 60 Placebo Controlled Trial 60 thyroxine 60 Sevelamer 60 indiplon capsules 60 troponins 60 HSCT 60 ELND# 60 HCV SPRINT 60 gefitinib Iressa 60 torezolid phosphate 60 corticosteroid dose 60 Phase #/#a 60 EndoTAG TM -1 60 Phenoptin 60 eosinophilic asthma 60 interleukin IL -6 60 DUROS 60 systemic immunosuppressive drugs 60 mGluR5 NAM 60 CRx 60 chromium supplementation 60 EDEMA3 60 CYP#A# substrate 60 Welchol 60 gonadotrophin releasing hormone GnRH 60 Cethromycin 60 serum glucose 60 Glatiramer Acetate 60 Phase IIA 60 multidose 60 platelet reactivity 60 FOSRENOL R 60 eltrombopag 60 CBLC# 60 BROVANA 60 trabedersen 60 probiotic supplementation 60 myocardial uptake 60 PREZISTA r 60 SRT# [003] 60 LEUKINE 60 CYP#A# CYP#D#